| Quarter | Call date | Disclosure | Financial quality | Kept | Missed | |
|---|---|---|---|---|---|---|
| Q2'26 | July 28, 2026 | 8/12 | 2 high, 3 medium, 2 low flags | 2 | 1 | Call sheet → |
| Q1'26 | April 28, 2026 | 11/12 | 2 medium, 4 low flags | 4 | 0 | Call sheet → |
| Q4'25 | February 10, 2026 | 10/12 | 1 medium, 5 low flags | 5 | 0 | Call sheet → |
| Marked | Status | Promise |
|---|---|---|
| Q2'26 | Missed | Full year EPS growth of 12-15% Quietly lowered to 7-10% growth while emphasizing dollar range |
| Q2'26 | Pending | Second half OI margin of 19% New commitment made this quarter |
| Q2'26 | Pending | 1 million pest devices by year-end At 800K currently, need 200K in 5 months |
| Q2'26 | Pending | Deliver 20% OI margin by 2027 Reaffirmed but with Cool IT dilution makes this harder |
| Q2'26 | Delivered | Life Sciences to deliver double-digit growth 15% growth in Q2, accelerating from 11% in Q1 |
| Q2'26 | Exceeded | Cool IT expected to grow 30%+ annually Actually growing 100%+ in Q1 2026, dramatically exceeding guidance |
| Q1'26 | Delivered | OVIVO to be off to strong start in 2026 (Q4 2025) Secured several new fabs, mid-teens growth expected, ahead of projections |
| Q1'26 | Exceeded | Growth engines to collectively grow double digits in 2026 (Q4 2025) High Tech 20%+, Life Sciences 11% (accelerating), Pest 7% - all exceeding expectations |
| Q1'26 | Pending | EPS growth of 12-15% for 2026 (Q4 2025) Q1 delivered 13% adjusted EPS growth, maintaining full-year 12-15% guide |
| Q1'26 | Pending | OI margin expansion of 100-150 basis points to more than 19% in 2026 (Q4 2025) Q1 organic OI margin expanded 70bps, on track for full-year target |
| Q1'26 | Delivered | Basic industries and paper performance to progressively improve in 2026 (Q4 2025) Beck confirms both businesses have 'stabilized' and 'reached the bottom' |
| Q1'26 | Pending | Distributor inventory impact to largely normalize in 2026 (Q4 2025) Not specifically addressed in Q1 call, still monitoring for Q2 impact |
| Q1'26 | Delivered | Volume growth to get back to 1% as we exit the first quarter (Q4 2025) Achieved exactly 1% volume growth in Q1 2026 - rare precision in forecasting |
| Q4'25 | Delivered | Double-digit EPS growth continuation Delivered 15% Q4 adjusted EPS growth, guided 12-15% for 2026 |
| Q4'25 | Delivered | Ovivo to more than double Global High-Tech business size Confirmed nearly $900M business size with Ovivo included |
| Q4'25 | Exceeded | One Ecolab to deliver $225M savings by 2027 Raised target to $325M with $100M+ already achieved |
| Q4'25 | Delivered | Operating income margin to reach 18% for full year 2025 Achieved exactly 18% full year as guided |
| Q4'25 | Pending | Basic Industries and Paper to return to growth during 2026 Softened language to 'progressively improve' but maintains 2026 timeline |
| Q4'25 | Exceeded | Life sciences bioprocessing to grow double digits in Q4 2025 Delivered 'best year yet' with nearly 75% ramp-up in bioprocessing |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.